Can a higher dose of infliximab tame stubborn rheumatoid arthritis?
NCT ID NCT00691028
First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study tested whether increasing the dose of infliximab (a drug that blocks inflammation) helps people with active rheumatoid arthritis who did not get enough relief from methotrexate alone. A total of 327 adults received three initial infusions of infliximab, then were given either the same or a higher dose every 8 weeks for about a year. Researchers measured joint pain, swelling, and other signs of disease activity to see if the higher doses worked better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Infliximab (also known as TA-650 or Remicade) given by intravenous infusion, plus methotrexate
What this could lead to
If successful, this study could show that a higher dose of infliximab helps control rheumatoid arthritis symptoms better than the standard dose in people who still have active disease despite methotrexate.
What could go wrong
This is a completed phase 3 trial, so results are already known. However, higher doses may increase the risk of serious infections or other side effects. The findings may not apply to all rheumatoid arthritis patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.